December 2024
Christmas holds different meanings for each of us, but one thing remains the same: it always marks the end of an autumn term. For us, this term has been packed with important milestones, and it feels like we've grown a few boot sizes, enabling us to take even bigger strides. Now, we quietly enter the holiday season and prepare to step into 2025 with renewed energy, ready to take giant leaps forward.
Wishing you all a very Merry Christmas,
Elin Trampe, CEO, Dicot Pharma
Now listed on Nasdaq First North
On November 7, the Stockholm Stock Exchange opened to the sound of Dicot Pharma’s bell ringing. This listing increases our visibility and attractiveness to institutional and international investors.
Full Steam Ahead in Phase 2a
Following regulatory approval, we quickly initiated screening, and dosing is now in full swing. The study aims to evaluate LIB-01’s effect on erectile function in men with erectile dysfunction. It is being conducted in Sweden, Denmark, and the Netherlands.
Q3 in Review
Read our latest quarterly report where among other things our Chairman Eva Sjökvist Saers reflects on the solid support we’ve received from shareholders, as demonstrated by the August rights issue.
Extended Patent Protection in the U.S.
We’ve been granted new patents that strengthen and extend both product and method protection in the U.S. until 2042. This includes "Composition of Matter" protection, covering the active substance in LIB-01—a particularly significant milestone.
Dicot at ESSM
In February, Professor François Giuliano will present our clinical results at the ESSM, Europe’s largest sexual medicine conference. “LIB-01 has the potential to become a game changer,” says Professor Giuliano.
Focus on Future Commercialization
We would like to introduce our new Chief Business Officer, Håkan Wickholm, an international business development expert with extensive experience, including several senior roles at AstraZeneca.
On Air at BIO-Europe
In November when attending the partnering conference BIO-Europe, Elin was interviewed by the American channel BiotechTV telling them all about the progress of our company.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.